Summary

Global Penicillin Drug Market is valued approximately at USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2021-2027. Penicillin is a widely used antibiotic produced from the Penicillium mould and used to treat a variety of bacterial infections. Their mode of action involves either breaking the bacteria's cell wall or slowing their development. Penicillin comes in a variety of forms to treat various illnesses, each of which is unique to one type of bacterium. Due to their versatility in use against many kinds of bacteria, they are now the most widely used antibiotics. Penicillin antibiotics are used to treat a variety of illnesses, including throat infections, meningitis, and others. The Penicillin drug market is driven by the key factor such as increasing R&D activities in the pharmaceutical industry and increasing burden of infectious diseases. For instance, according to an article titled "Community-Acquired Pneumonia" by H. Regunath (2020), the projected global incidence of community-acquired pneumonia ranges from 1.5 to 14 cases per 1000 person-years. Furthermore, infectious infections remain a significant cause of death for children under the age of five, particularly in Sub-Saharan Africa and Southern Asia, despite several advances in combating paediatric illnesses. Pneumonia (15%), diarrhoea (8%), and malaria (5%) remain among the major causes of mortality for children under the age of five, according to the UNICEF study "Levels and Trends in Child Mortality" published in 2019. However, discovery and fierce competition with new class of diverse antibacterial may impede market growth over the forecast period of 2021-2027.

The Penicillin Drug market is dominated by North America, which is projected to continue dominating the entire market during the forecast period. The rising burden of infectious illnesses, which leads to an increase in the use of different antibiotics, is the main driver of this region’s market growth.

Major market player included in this report are:
FUJIFILM Toyama Chemical Co., Ltd
Pfizer, Inc.
Astellas Pharma, Inc.
Sun Pharmaceutical Industries
Cipla Limited
GlaxoSmithKline plc
Daiichi Sankyo Company Ltd.
Lupin Limited
Merck Co. and Inc.
Novartis AG



The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Bulk
Dosage
By Type:
Aminopenicillin
Antipseudomonal Penicillin
Beta-lactamase Inhibitor
Natural Penicillin
Penicillinase-resistant Penicillin
By Manufacturing process:
Synthetic Process
Natural Process
Semisynthetic Process
By End user:
Hospitals
Clinics
Research Institutes
Others
By Mode of delivery:
Oral
Intramuscular
Intravenous
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027.

Target Audience of the Global Penicillin Drug Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors